Novartis

Novartis plots new course for Sandoz
Novartis plots new course for Sandoz
BioCentury
Novartis
Sandoz
generics
Flag link:
As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices
As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices
BioSpace
Novartis
drug pricing
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Flag link:
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Biopharma Dive
drug pricing
Pfizer
Novartis
Amgen
Flag link:
Novartis urges Britain to secure drug supplies before Brexit
Novartis urges Britain to secure drug supplies before Brexit
Yahoo/Reuters
Novartis
UK
Brexit
Europe
drug shortages
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:
Sandoz launches EpiPen rival at $250 per two-pack
Sandoz launches EpiPen rival at $250 per two-pack
BioPharma Dive
Sandoz
Novartis
EpiPens
Symjepi
Flag link:
Novartis teams up with Oxford researchers to crunch big data into clinical insights
Novartis teams up with Oxford researchers to crunch big data into clinical insights
Endpoints
Novartis
University of Oxford
Vas Narasimhan
machine learning
artificial intelligence
Flag link:
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So Hard
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So Hard
Forbes
Novartis
Pharma CEOs
Vas Narasimhan
digital pharma
Flag link:
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
BioSpace
Massachusetts
Novartis
SMA
gene therapy
Kymriah
Flag link:
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
BioSpace
FDA
Amneal
generics
Novartis
Exelon Patch
Alzheimer's disease
Parkinson's Disease
Flag link:
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Fierce Pharma
Allergan
Botox
migraines
CGRP blockers
Amgen
Novartis
Aimovig
Teva Pharmaceutical
Ajovy
Eli Lilly
Emgality
Flag link:
NASH Space in Focus in 2019 as Firms Look to Diversify
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
Flag link:
NICE turns down Novartis' Aimovig, flagging clinical trial concerns
NICE turns down Novartis' Aimovig, flagging clinical trial concerns
Biopharma Dive
NICE
UK
Amgen
Novartis
migraines
Aimovig
Flag link:
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Flag link:
Novartis Defends Itself Against Kickback Allegations from Former Employee
Novartis Defends Itself Against Kickback Allegations from Former Employee
BioSpace
Novartis
kickbacks
whistleblower lawsuits
breast cancer
Flag link:
Novartis puts AI on the job to help reps say the right things to the right doctors
Novartis puts AI on the job to help reps say the right things to the right doctors
Fierce Pharma
Novartis
digital technology
drug reps
artificial intelligence
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact
In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact
Fierce Biotech
Novartis
Xencor
bispecific antibodies
Flag link:
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Fierce Pharma
Novartis
Pharma CEOs
CAR-T
Kymriah
Vas Narasimhan
JPMHC 2019
Flag link:

Pages